Antithrombin
Authors:
M. Matýšková 1; M. Šlechtová 1; J. Zavřelová 1; I. Hrachovinová 2; M. Penka 1
Authors‘ workplace:
Oddělení klinické hematologie, Fakultní nemocnice Brno
1; Ústav hematologie a krevní transfuze, Praha
2
Published in:
Transfuze Hematol. dnes,19, 2013, No. 4, p. 244-249.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Antithrombin is one the most important serine protease inhibitors (termed the serpin family), especially of thrombin and factor Xa. Its inherited deficiency is associated with an increased risk of venous thrombosis, pulmonary embolism and thrombosis in atypical localizations. There are even a few reports about arterial thrombosis associated with this deficiency. Pregnancy complications can occur in women with antithrombin deficiency. We use functional assays are used to determine antithrombin (inhibitory) activity in the laboratory. The antigenic assay is used only to define the type of deficiency in the case of impaired antithrombin activity. FXa inhibition-based antithrombin assays appear to be the most widely used routine method. It is important to realize that it is possible that not all type II deficiencies can be detected using this assay as various defects have different findings and the results can in some cases be within normal range. In such cases, the diagnosis can be made only by genetic analysis.
Key words:
antithrombin, inherited deficiency, thromboembolic disease, laboratory examination
Sources
1. Owen Ch A. A history of blood coagulation. May Foundation for Medical Education and Research Rochester, Minnesota 2001: 97-102.
2. Pizzo SV. The physiological role of antithrombin III as an anticoagulant. Sem Hematol 1994; 31(2)Suppl 1: 4-7.
3. Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 2011; 9(Suppl 1): 26-34.
4. Law RHP, Zhang Q, McGowan S, et al. An overview of the serpin superfamily. Genome Biol 2006; 7: 216.11.
5. Hernández-Espinosa D, Ordóñez A, Vicente V, Corral J. Factors with conformational effects on haemostatic serpins: Implications in thrombosis. Thromb Haemost 2007; 98(3): 557-563.
6. Olds RJ, Lane DA, Mille B, et al. Antithrombin: The principal inhibitor of thrombin. Sem Thromb Hemost 1994; 20(4): 353-372.
7. McCoy AJ, Pei XY, Skinner R, Abrahamns J-P, Carrell RW. Structure of beta-antithrombin and the effect of glycosylation on antithrombin‘s heparin affinity and activity. J Mol Biol 2003; 326(3): 823-833.
8. Tait RC, Walker ID, Islam AM, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-480.
9. Niessen RWLM, Lamping RJ, Jansen PM, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Hemost 1997; 78: 1088-1092.
10. Fourrier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C. Coagulation inhibitor substitution during sepsis. Int Care Med 1995; 21: S264-S268.
11. Ragazzi M, Ferro DR. Conformation of the pentasacharide corresponding to the binding site of heparin for antithrombin III. Carbohydrate Res 1990; 195: 169-185.
12. Zhang W, Chuang Y-J, Swanson R, et al. Angiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-1191.
13. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1329.
14. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the SSC ISTH. Thromb Haemost 1997; 77: 197-211.
15. Antithrombin Mutation Database. http://www1.imperial.ac.uk/departmentofmedicine/divisions/experimentalmedicine/haematology/coag/antithrombin/
16. Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int Jnl Lab Hem 2011; 33: 227-237.
17. Luxembourg B, Delev D, Geisen CH, et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
18. Martínez-Martínez I, Johnson DJD, Yamasaki M, et al. Type II antithrombin deficiency caused by a large in-frame insertion: structural, functional and pathological relevance. J Thromb Haemost 2012; 10(9): 1859-1866.
19. Bucciarelli P, Passamonti SM, Biguzzi E, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost 2012; 10: 1783-1791.
20. Hule V. Vrozené rodinné snížení antitrombinu III. Vnitř Lék 1977; 23(9): 887-892.
21. Martínez-Martínez I, Ordóñez A, Navarro-Fernández J, et al. Antithrombin Murcia (K241E) causing antithrombin deficiency: a pos-sible role for altered glycosylation. Haematologica 2010; 95(8): 1358-1365.
22. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: A cross-sectional Study. Am J Hematol 1994; 45: 321-324.
23. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87(1): 106-112.
24. Corral J, Hernández-Espinosa D, Soria JM. Antithrombin Cambridge II (A384S): an underestimated risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
25. Kottke-Marchant K, Duncan A. Antithrombin deficiency. Issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336.
26. Chowdhury V, Lane DA, Mille B, et al. Homozygous antithrombin deficiency: Report of two new cases (99Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
27. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106(7): 873–878.
28. Lane DA, Olds RR, Thein S-L. Antithrombin and its deficiency states. Blood Coag Fibrinol 1992; 3: 315-341.
29. Wilson RF, Mammen EF, Tyburski JG, Warsow KM, Kubinec SM. Antithrombin levels related to infection and outcome. J Trauma Injury Infection Crit Care 1996; 40(3): 384-387.
30. Penner J. Antithrombin Deficiency in special clinical syndromes – Part II: Trauma/burns. Sem Hematol 1995; 32(4, Suppl 2): 42-47.
31. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event. In carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-464.
32. Lijfering WM, Brouwer J-LP, Veeder NJGM, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-5322.
33. Pabinger I, Schneider B, for the Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. Arteiol Thromb Vasc Biol 1996; 16: 742-748.
34. Roldán V, Ordóñez A, Marín F, et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2009; 101: 483-486.
35. Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell M.R. Thrombo-embolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-Asp). J Clin Invest 1994; 94: 2265-2274.
36. van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TKAB, de Graefft PA, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167: 282-289.
37. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75(3): 387-388.
38. Roqué H, Paidas MJ, Funai EF, Kuczynski E, Lockwood ChJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 290-295.
39. Folkeringa N, Brouwer JLP, Korteweg FJ, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136: 656-661.
40. Hrachovinová I, Habart D, Salaj P, Matýšková M, Vorlová Z. Molecular basis of inherited defect of antithrombin in ten Czech families. Čas Lék Čes 2000; 139(19): 595-597.
41. Matýšková M, Šlechtová M, Zavřelová J, Penka M. Combined FV Leiden and antithrombin deficiency in women. Thrombosis Res 2009; 123(Suppl 2): S155, Abstract P55.
42. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85: 947-950.
43. Matýšková M, Zavřelová J, Čech Z. Hemokoagulační laboratorní vyšetření. In: Penka M, Buliková A, a kol. Neonkologická hematologie. 2. vyd. Praha, Grada Publishing, a.s., 2009; 199-217.
44. Demers Ch, Henderson P, Blajchman MA, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69(3): 231-235.
45. Merz M, Böhm-Weigert M, Braun S, et al. Clinical multicenter evaluation of a new FXa-based antithrombin assay. Int J Lab Hem 2011; 33: 498-506.
46. Kristensen SR, Rasmusen B, Pedersen S, Bathum L. Detecting antithrombin deficiency may be a difficult task – more than one test is necessary J Thromb Haemost 2007; 5: 617-618.
47. Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blombäck M. Discrepancy between antithrombin activity methods revealed in antithrombin Stockholm? Do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002; 99(6): 2271-2272.
48. Beauchamp NJ, Pike RN, Daly M. Antithrombins Wibble and Wobble (T85M/K): Archetypal conformational disease with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-2706.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 4
Most read in this issue
- Phlebotomy and therapeutic apheresis in the treatment of polyglobulia
- Antithrombin
- Stability of coagulation factors in thawed plasma
- Malignant tumours in adult patients after successful treatment of acute myeloid leukemia: long-term experience at the Department of Hemato-Oncology in Olomouc